Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Role of RLIP76 in doxorubicin resistance in lung cancer Vatsyayan R; Chaudhary P; Lelsani PC; Singhal P; Awasthi YC; Awasthi S; Singhal SSInt J Oncol 2009[Jun]; 34 (6): 1505-11Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.|*Drug Resistance, Neoplasm[MESH]|ATP-Binding Cassette Transporters/*physiology[MESH]|Antibiotics, Antineoplastic/*therapeutic use[MESH]|Doxorubicin/*therapeutic use[MESH]|GTPase-Activating Proteins/*physiology[MESH]|Humans[MESH]|Lung Neoplasms/*drug therapy/*metabolism[MESH] |